Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anaferon for Children in Acute Upper Respiratory Infections
NCT03162458Phase 3Completed
- Sponsor
- Materia Medica Holding
- Start
- Jan 2015
- Primary completion
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute upper respiratory infection (URI) comparing Anaferon with Placebo (2 arms). Primary endpoints: Average Illness Duration (Time to Recovery/Improvement) at 14 days and Severity of the Disease Within 5 Days (Area Under the Curve for Total Symptom Score). Started Jan 2015; status: completed.
02
Drugs
anaferon
03
Conditions
acute upper respiratory infection (URI)
Beyond the preview
Go deeper on NCT03162458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03162458.